These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story.
    Author: Froissart A, Veyradier A, Hié M, Benhamou Y, Coppo P, French Reference Center for Thrombotic Microangiopathies.
    Journal: Eur J Intern Med; 2015 Nov; 26(9):659-65. PubMed ID: 26293834.
    Abstract:
    Despite a significant improvement of thrombotic thrombocytopenic purpura (TTP) prognosis since the use of plasma exchange, morbidity and mortality remained significant because of poor response to standard treatment or exacerbations and relapses. Rituximab, a chimeric monoclonal antibody directed against the B-lymphocyte CD20 antigen, has shown a particular interest in this indication. Recent studies also reported strong evidence for its efficiency in the prevention of relapses. This review addresses these recent progresses and still opened questions in this topic: should rituximab be proposed in all patients at the acute phase? Should all patients benefit from a preemptive treatment? Is the infectious risk acceptable in this context?
    [Abstract] [Full Text] [Related] [New Search]